UNITED THERAPEUTICS Corp (UTHR): who owns it and who trades it
As of Nov 16, 2026, UTHR insiders reported 2899 open-market sales worth $1.5B and 1 purchase worth $864K in the last 12 months, with 13% of the sale value made under pre-set 10b5-1 plans. The largest seller was Martine A Rothblatt (CEO), with $976M. 8 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling United Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns UTHR
877 funds and institutions reported UTHR shares worth $22.7B at the end of Q2 2026, about 99% of the company. The largest holder is BlackRock, Inc. with 12.5%.
Funds and institutions (13F) 99%Everyone else 1%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 5.29M | 12.47% | $2.9B | -2% |
| Avoro Capital Advisors LLC | 2.78M | 6.54% | $1.5B | +6% |
| Vanguard Portfolio Management LLC | 1.92M | 4.52% | $1B | -4% |
| Vanguard Capital Management LLC | 1.92M | 4.52% | $1B | -2% |
| State Street Corp | 1.90M | 4.47% | $1B | +3% |
| Renaissance Technologies LLC | 1.71M | 4.03% | $926M | -4% |
| Wellington Management Group LLP | 1.38M | 3.25% | $747M | -39% |
| Geode Capital Management, LLC | 996,598 | 2.35% | $539M | -19% |
| Jupiter Topco LLC | 831,129 | 1.96% | $450M | – |
| Norges Bank | 694,753 | 1.64% | $376M | – |
| Assetmark, Inc | 624,068 | 1.47% | $338M | +1% |
| AQR Capital Management LLC | 546,002 | 1.29% | $295M | -34% |
| Dimensional Fund Advisors LP | 527,904 | 1.24% | $286M | +3% |
| FMR LLC (Fidelity) | 473,409 | 1.12% | $257M | -10% |
| Invesco Ltd. | 473,109 | 1.11% | $256M | -22% |
| Baillie Gifford & Co | 467,209 | 1.10% | $253M | +9% |
| Deerfield Management Company, L.P. | 457,000 | 1.08% | $248M | No change |
| Morgan Stanley | 436,699 | 1.03% | $237M | +7% |
| Vestal Point Capital, LP | 435,000 | 1.02% | $236M | +480% |
| Northern Trust Corp | 430,844 | 1.02% | $233M | -1% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, UTHR insiders reported $864K of open-market purchases and $1.5B of sales. 13% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 528 | $587.42 | $310K | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 493 | $588.61 | $290K | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 603 | $589.80 | $356K | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,657 | $590.65 | $979K | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 2,181 | $591.56 | $1.3M | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 518 | $592.61 | $307K | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 245 | $593.81 | $145K | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,275 | $594.65 | $758K | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,040 | $595.41 | $619K | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 480 | $596.65 | $286K | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 440 | $597.48 | $263K | Form 4 |
| Nov 13, 2026 | Martine A Rothblatt | CEO | Sale plan | 40 | $598.83 | $24K | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 159 | $587.00 | $93.3K | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 323 | $588.30 | $190K | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 427 | $589.21 | $252K | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 359 | $590.11 | $212K | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 317 | $591.10 | $187K | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 551 | $592.32 | $326K | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,934 | $593.44 | $1.1M | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 3,079 | $594.24 | $1.8M | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,409 | $595.17 | $839K | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 662 | $596.22 | $395K | Form 4 |
| Nov 12, 2026 | Martine A Rothblatt | CEO | Sale plan | 280 | $597.33 | $167K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 25 | $584.20 | $14.6K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 215 | $585.93 | $126K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 320 | $586.59 | $188K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 271 | $588.16 | $159K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 292 | $589.18 | $172K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 301 | $590.31 | $178K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 736 | $591.56 | $435K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,172 | $592.68 | $695K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 961 | $593.57 | $570K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 991 | $594.66 | $589K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,346 | $595.46 | $801K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,324 | $596.74 | $790K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,299 | $597.61 | $776K | Form 4 |
| Nov 11, 2026 | Martine A Rothblatt | CEO | Sale plan | 247 | $598.63 | $148K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 40 | $577.52 | $23.1K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 880 | $580.40 | $511K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 742 | $581.36 | $431K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 618 | $582.42 | $360K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 980 | $583.64 | $572K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 328 | $584.76 | $192K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 795 | $585.56 | $466K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 937 | $586.66 | $550K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 620 | $587.96 | $365K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 360 | $589.15 | $212K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 2,040 | $589.95 | $1.2M | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 960 | $590.95 | $567K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 120 | $592.20 | $71.1K | Form 4 |
| Nov 10, 2026 | Martine A Rothblatt | CEO | Sale plan | 80 | $592.93 | $47.4K | Form 4 |
| Nov 9, 2026 | Christopher Patusky | Director | Sale | 1,210 | $580.00 | $702K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 80 | $556.52 | $44.5K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 161 | $558.07 | $89.8K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 168 | $558.70 | $93.9K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 71 | $559.80 | $39.7K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 517 | $561.15 | $290K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 512 | $562.35 | $288K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 291 | $563.49 | $164K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 160 | $564.36 | $90.3K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 220 | $565.56 | $124K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 300 | $566.57 | $170K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 400 | $567.48 | $227K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 240 | $569.21 | $137K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 280 | $570.22 | $160K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 322 | $571.78 | $184K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 358 | $572.62 | $205K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 280 | $573.94 | $161K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 85 | $574.91 | $48.9K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 315 | $576.37 | $182K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 120 | $577.45 | $69.3K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 160 | $578.45 | $92.6K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 294 | $579.58 | $170K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 300 | $580.16 | $174K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 520 | $581.52 | $302K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,732 | $582.79 | $1M | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 494 | $583.80 | $288K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 840 | $584.70 | $491K | Form 4 |
| Nov 9, 2026 | Martine A Rothblatt | CEO | Sale plan | 280 | $585.63 | $164K | Form 4 |
| Nov 6, 2026 | Martine A Rothblatt | CEO | Sale plan | 109 | $560.79 | $61.1K | Form 4 |
| Nov 6, 2026 | Martine A Rothblatt | CEO | Sale plan | 2,005 | $561.80 | $1.1M | Form 4 |
| Nov 6, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,136 | $562.87 | $639K | Form 4 |
| Nov 6, 2026 | Martine A Rothblatt | CEO | Sale plan | 870 | $563.85 | $491K | Form 4 |
| Nov 6, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,776 | $564.99 | $1M | Form 4 |
| Nov 6, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,742 | $565.85 | $986K | Form 4 |
| Nov 6, 2026 | Martine A Rothblatt | CEO | Sale plan | 1,021 | $566.83 | $579K | Form 4 |
| Nov 6, 2026 | Martine A Rothblatt | CEO | Sale plan | 761 | $567.64 | $432K | Form 4 |
| Nov 6, 2026 | Martine A Rothblatt | CEO | Sale plan | 80 | $568.68 | $45.5K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 320 | $562.51 | $180K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 520 | $563.98 | $293K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 720 | $565.32 | $407K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 462 | $566.59 | $262K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 156 | $567.93 | $88.6K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 280 | $568.86 | $159K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 562 | $570.53 | $321K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 585 | $571.67 | $334K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 375 | $572.61 | $215K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 320 | $573.93 | $184K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 320 | $574.46 | $184K | Form 4 |
| Nov 5, 2026 | Martine A Rothblatt | CEO | Sale plan | 221 | $576.17 | $127K | Form 4 |
Latest 100 of 2900 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Martine A Rothblatt | Chairperson & CEO, Director | $864K | $976M | Nov 13, 2026 |
| James Edgemond | CFO AND TREASURER | – | $193M | Jun 22, 2026 |
| Michael Benkowitz | PRESIDENT AND COO | – | $159M | Feb 23, 2026 |
| Paul A Mahon | EVP & GENERAL COUNSEL | – | $109M | Nov 5, 2026 |
| Christopher Patusky | Director | – | $3.4M | Nov 9, 2026 |
| Louis W Sullivan | Director | – | $3M | Dec 22, 2025 |
| Tommy G Thompson | Director | – | $2.5M | Mar 26, 2026 |
| Ray Kurzweil | Director | – | $2.4M | Mar 4, 2026 |
| Christopher Causey | Director | – | $2.3M | Mar 30, 2026 |
| Judy D. Olian | Director | – | $417K | Mar 23, 2026 |
| Jan Malcolm | Director | – | $373K | Jul 10, 2026 |
| Nilda Mesa | Director | – | $356K | Sep 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
UTHR short interest
Low short interest. 4.3% of UTHR shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went down 20%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.84M UTHR shares were sold short, 4.3% of the shares outstanding, down 25.2% from the report before. At the average daily volume of 532,166 shares, buying them all back would take about 3.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.84M | 4.31% | -25% | 532,166 | 3.5 |
| Oct 15, 2026 | 2.46M | 5.73% | -32% | 957,670 | 2.6 |
| Sep 30, 2026 | 3.60M | 8.39% | +28% | 995,621 | 3.6 |
| Sep 15, 2026 | 2.80M | 6.53% | +36% | 717,303 | 3.9 |
| Aug 31, 2026 | 2.06M | 4.80% | -2% | 428,339 | 4.8 |
| Aug 14, 2026 | 2.11M | 4.93% | -9% | 599,841 | 3.5 |
| Jul 31, 2026 | 2.32M | 5.42% | +11% | 420,429 | 5.5 |
| Jul 15, 2026 | 2.09M | 4.92% | -1% | 378,601 | 5.5 |
| Jun 30, 2026 | 2.12M | 4.99% | +3% | 727,504 | 2.9 |
| Jun 15, 2026 | 2.05M | 4.84% | -6% | 442,844 | 4.6 |
| May 29, 2026 | 2.19M | 5.16% | -5% | 484,885 | 4.5 |
| May 15, 2026 | 2.30M | 5.43% | -6% | 463,580 | 5.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded UTHR
Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 2 sales of UTHR. The latest was a sale by Lisa C. McClain on Oct 31, 2025, reported Nov 21, 2025.
Purchases 2Sales 2
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Oct 31, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 30, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 30, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Jun 11, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
United Therapeutics company events
United Therapeutics filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 22, 2026AnnouncementThe Board of Directors of United Therapeutics Corporation (the Company ) approved a share repurchase program (the Share Repurchase Program ), authorizing the purchase by the Company of up to $2.0 billion of the Company’s common stock. Filing
- Oct 14, 2026AnnouncementUnited Therapeutics Corporation ( UT ) entered into a Settlement Agreement (the Settlement Agreement ) with Liquidia Technologies, Inc. ( Liquidia ) that provides for the resolution of pending litigation between the parties, as noted below: · UT v. Filing
- Sep 8, 2026AgreementUnited Therapeutics Corporation (the Company ) entered into an accelerated share repurchase agreement (the ASR Agreement ) with Citibank, N.A. ( Citi ) to repurchase approximately $477.6 million in the aggregate of the Company’s common stock ( Common Stock ) under the Company’s previously announced… Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 23, 2026LeadershipThe Board of Directors (the Board ) of United Therapeutics Corporation (the Company ), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board. Filing
- Jun 29, 2026LeadershipAs described in Item 5.07 below, on June 26, 2026, at the 2026 Annual Meeting of Shareholders of United Therapeutics Corporation (the Company ), the Company’s shareholders approved the United Therapeutics Corporation 2026 Stock Incentive Plan (the 2026 Plan ). Filing
- May 6, 2026ResultsReleased financial results. Filing
- Mar 30, 2026AnnouncementUnited Therapeutics Corporation issued a press release announcing positive results of the TETON-1 clinical study of Tyvaso ® (treprostinil) Inhalation Solution in patients with idiopathic pulmonary fibrosis. Filing
- Mar 9, 2026AgreementThe Board of Directors (the Board ) of United Therapeutics Corporation (the Company ) approved a share repurchase program (the Share Repurchase Program ), authorizing the purchase by the Company of up to $2.0 billion of the Company’s common stock ( Common Stock ) before March 9, 2027. Filing
- Mar 2, 2026AnnouncementShared information with investors. Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Jan 22, 2026LeadershipThe Board of Directors of United Therapeutics Corporation, acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Kevin J. Tracey, M.D., to serve as a member of the Board. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
United Therapeutics financials
Famous investors that hold UTHR
8 of the 50 well-known investors we track reported holding UTHR in their latest 13F filing. The largest position is Jim Simons's, worth $908M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.68M | $908M | 1.2% | -2% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 928,464 | $503M | 0.3% | +205% |
| Israel Englander · Millennium Management | Q3 2026 | 297,424 | $161M | 0.1% | -27% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 176,950 | $95.9M | 0.2% | -12% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 125,394 | $67.9M | 0.3% | +13% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 38,973 | $21.1M | 0.0% | +15% |
| Jeremy Grantham · GMO | Q3 2026 | 3,726 | $2M | 0.0% | +14% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 1,219 | $661K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named UTHR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 4, 2026 | Martine A. Rothblatt | 13G/A | 4.0% |
| Nov 4, 2026 | Martine A. Rothblatt | 13G/A | 4.0% |
Questions about UNITED THERAPEUTICS Corp (UTHR) stock
Who owns the most UTHR stock?
The largest reported owner of UNITED THERAPEUTICS Corp (UTHR) is BlackRock, Inc., with 12.5% of the company. In total, 877 funds and institutions reported holding UTHR at the end of Q2 2026, together about 99% of the shares. See the largest owners.
Are UTHR insiders buying or selling?
In the last 12 months, UTHR insiders reported 1 open-market purchase worth $864K and 2,899 sales worth $1.5B. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in UTHR?
As of Oct 30, 2026, 1.84M UTHR shares were sold short, 4.3% of the shares outstanding, down 25.2% from the report before. At the average daily volume of 532,166 shares, buying them all back would take about 3.5 trading days (days to cover). See the history.
Have members of Congress traded UTHR?
Yes. 1 member of Congress reported 2 purchases and 2 sales of UTHR since Nov 17, 2024. The latest was reported on Nov 21, 2025. See the trades.
Which famous investors hold UTHR?
8 of the 50 well-known investors we track reported UTHR in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $908M. See all holders.
Executive pay
United Therapeutics's chief executive was paid a total of $18M for the year ended Dec 31, 2025, down 22% from $23M the year before. In the last 12 months, United Therapeutics's executives and directors bought $864K of stock on the open market and sold $1.5B.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.